We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
News

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
News

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Calando Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) have approved its investigational new drug application (IND) for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase—a clinically-validated cancer target—formulated with Calando’s proprietary RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymer delivery system.

The FDA approval allows the initiation of a Phase I trial that will be conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California, and the South Texas Accelerated Research Therapeutics (START) clinic in San Antonio, Texas. It will be led by Drs. Antoni Ribas (UCLA) and Anthony Tolcher (START).

“We are pleased to have received FDA approval of our IND application for CALAA-01,” said Jeremy Heidel, CSO of Calando. “We look forward to initiating a Phase I clinical trial with CALAA-01 that we believe will be the first clinical study using targeted, systemic delivery of siRNA in an oncology setting. The entire Calando team is excited to be at the forefront of this new area for therapeutic development.”

Advertisement